Glaxo Wellcome/SmithKline Beecham
Executive Summary
Glaxo Chairman Richard Sykes "thinks" the early 1998 break-up of merger talks between the two companies is "the end of the story," but believes that the logic behind the merger is still compelling. "I think there's been enough said about the merger breakdown," Sykes told a July 30 press conference in London. "There really is nothing more to say about it. The logic is still there, the reasons for doing a merger like that are still there, they're still compelling, but that was just an opportunity: it didn't work out, and I think that's the end of the story." Glaxo management is understood to have been working over the summer to try to resurrect the deal
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth